Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative MEDI0562 in Head and Neck Squamous Cell Carcinoma or Melanoma
NCT03336606Phase 1Completed
- Start
- Jul 2018
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tavolimab in head and neck squamous cell carcinoma (HNSCC) and melanoma (2 cohorts). Primary endpoint: Activation of immune response at 28 days. Started Jul 2018; status: completed.
02
Drugs
tavolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT03336606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03336606.